Overview
Anogenital human papillomavirus (HPV) infection is a common sexually transmitted infection linked to various cancers, including cervical, anal, and oropharyngeal cancers, as well as genital warts 12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970.Diagnosis
Management
References
1 Rosenberg K. One dose of HPV vaccine is noninferior to two doses. The American journal of nursing 2026. link 2 Chen JH, Chen M, Wu ZY, Luo QM, Tu YY. Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014-2024. Frontiers in public health 2026. link 3 Yihan W, Wang J, Zhu Y, Sun L, Li J, Wang Y et al.. Adverse event following immunization with domestic bivalent human papillomavirus vaccine in Hebei Province, China (2022-2024). Human vaccines & immunotherapeutics 2026. link 4 Paudel P, Sah A. A meta-analysis of the prevalence, genotype distribution and risk factors for human papillomavirus infection in Nepal. PloS one 2025. link 5 Fu X, Xia Y, Zhou W, Lu Y. Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis. Expert review of vaccines 2025. link 6 Himeles JR, McKenzie C, Manduca S, Shaw KS, Jones Z, Nagler A et al.. Same-day human papilloma virus vaccination improves vaccine uptake in a dermatology sexually transmitted infection clinic: A quality improvement-based model for improving vaccination rates. Journal of the American Academy of Dermatology 2025. link 7 Nakai M, Oka E, Ueda Y, Yagi A, Masuda T, Kakuda M et al.. A ninth-year follow-up survey of attitudes and behaviors of obstetricians and gynecologists toward HPV vaccination in Japan. Scientific reports 2025. link 8 Ceasar J, Frank EM, Hall R, Hartert C, Onks C. Alternative Allied Health Care Providers: Athletic Trainers Educating Stakeholders to Improve HPV-Related Infections. Journal of primary care & community health 2025. link 9 Rahman MM, Masum MHU, Parvin R, Das SC, Talukder A. Designing of an mRNA vaccine against high-risk human papillomavirus targeting the E6 and E7 oncoproteins exploiting immunoinformatics and dynamic simulation. PloS one 2025. link 10 Liu Q, Liang G, Song Y. Adverse events following 9-valent human papillomavirus vaccine (GARDASIL® 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015-2024. Human vaccines & immunotherapeutics 2025. link 11 Su Y, Huang Y, Wei J, Wang X, Zhou Y, Wu X et al.. Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports. Human vaccines & immunotherapeutics 2025. link 12 Setiawan D, Nurulita NA, Khoirunnisa SM, Postma MJ. The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women. PloS one 2024. link 13 Choi CI, Lee SJ, Choi JB, Kim TH, Lee JW, Kim JM et al.. 2023 Korean sexually transmitted infections guidelines by the Korean Association of Urogenital Tract Infection and Inflammation: Human papillomavirus vaccination. Investigative and clinical urology 2024. link 14 Yu Y, Hao J, Mohamed SB, Fu S, Zhao F, Qiao Y. The prevalence of multiple or single HPV infection and genotype distribution in healthy Chinese women: A systemic review. Journal of cancer research and therapeutics 2024. link 15 Cagle-Colon KJ, Voigt P, Boyd L. HPV Vaccination Practices Among Medical Trainees in Pediatrics, Obstetrics and Gynecology, and Family Medicine. Journal of lower genital tract disease 2024. link 16 Khalili SM, Rafiei EH, Havaei M, Alizadeh L, Ghahremani F, Keshavarz Z et al.. Relationship between human papillomavirus and serum vitamin D levels: a systematic review. BMC infectious diseases 2024. link 17 Wu CF, Highfield L, Swint JM, Lairson DR. Provider-Based HPV Vaccine Promotion Interventions: A Meta-analysis. Pediatrics 2023. link 18 Guo J, Guo S, Dong S. Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis. Frontiers in public health 2023. link 19 Lin R, Jin H, Fu X. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis. Expert review of vaccines 2023. link 20 Ezechi O, Akinsolu F, Salako A, Abodunrin O, Adewole I, Olagunju M et al.. High-risk human papillomavirus infection among Nigerian women: A systematic review and meta-analysis. The Journal of international medical research 2023. link 21 Davies C, Marshall HS, Brotherton JML, McCaffery K, Kang M, Macartney K et al.. Complex intervention to promote human papillomavirus (HPV) vaccine uptake in school settings: A cluster-randomized trial. Preventive medicine 2023. link 22 Vasli P, Zahedinia S, Hosseini M, Nasiri M. A Protection Motivation Theory-Based Empowerment Intervention for Promoting Health Behaviors in Women With Human Papillomavirus: An Experimental Study. Sexually transmitted diseases 2023. link 23 Huang R, Gan R, Zhang D, Xiao J. The comparative safety of human papillomavirus vaccines: A Bayesian network meta-analysis. Journal of medical virology 2022. link 24 McClymont E, Faber MT, Lindquist S, Bone JN, Kjær SK. Human Papillomavirus Infection Among Pregnant Women Living With HIV: A Systematic Review and Meta-Analysis. Journal of acquired immune deficiency syndromes (1999) 2022. link 25 Kechagias KS, Kalliala I, Bowden SJ, Athanasiou A, Paraskevaidi M, Paraskevaidis E et al.. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ (Clinical research ed.) 2022. link 26 Martins J, Carvalho C, Freitas F, Monteiro P. New paradigm of human papillomavirus infection. Portuguese journal of cardiac thoracic and vascular surgery 2022. link 27 Normile D. Japan reboots HPV vaccination drive after 9-year gap. Science (New York, N.Y.) 2022. link 28 Herzum A, Ciccarese G, Drago F, Pastorino A, Dezzana M, Mavilia MG et al.. Cervical, oral and anal Human papillomavirus infection in women attending the Dermatology Unit of a regional reference hospital in Genoa, Italy: a prevalence study. Journal of preventive medicine and hygiene 2022. link 29 Zheng C, Zheng Z, Chen W. Association between serum vitamin C and HPV infection in American women: a cross-sectional study. BMC women's health 2022. link 30 Chen F, Pan X, Liang H, Shen L, Wang Y, Chen Y et al.. Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021. Human vaccines & immunotherapeutics 2022. link 31 Gross GE, Werner RN, Avila Valle GL, Bickel M, Brockmeyer NH, Doubek K et al.. German evidence and consensus-based (S3) guideline: Vaccination recommendations for the prevention of HPV-associated lesions. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2021. link 32 Taylor AC, Hopkins LW, Moore G. Increasing human papillomavirus immunization in the primary care setting. The Nurse practitioner 2021. link 33 Bonaldo G, Montanaro N, Vaccheri A, Motola D. Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System. British journal of clinical pharmacology 2021. link 34 Sonawane K, Lin YY, Damgacioglu H, Zhu Y, Fernandez ME, Montealegre JR et al.. Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA network open 2021. link 35 Hu Y, Pan X, Shen L, Chen F, Wang Y, Liang H et al.. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020. Human vaccines & immunotherapeutics 2021. link 36 . Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809. Obstetrics and gynecology 2020. link 37 Phillips A, Hickie M, Totterdell J, Brotherton J, Dey A, Hill R et al.. Adverse events following HPV vaccination: 11 years of surveillance in Australia. Vaccine 2020. link 38 Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and mortality weekly report 2019. link 39 Steben M, Durand N, Guichon JR, Greenwald ZR, McFaul S, Blake J. A National Survey of Canadian Physicians on HPV: Knowledge, Barriers, and Preventive Practices. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2019. link 40 Martakis K, Alexander D, Schloemer T, Blair M, Rigby M, Schröder-Bäck P. Human papillomavirus vaccination and respect for children's developing autonomy: Results from a European Union wide study. Journal of child health care : for professionals working with children in the hospital and community 2019. link 41 Donahue JG, Kieke BA, Lewis EM, Weintraub ES, Hanson KE, McClure DL et al.. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics 2019. link 42 Mauro AB, Fernandes EG, Miyaji KT, Arantes BA, Valente MG, Sato HK et al.. Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016). Revista do Instituto de Medicina Tropical de Sao Paulo 2019. link 43 Schartau S, Heering Holt D, Lützen T, Rytter D, Mølbak K. On the contextual nature of vaccine safety monitoring: Adverse events reporting after HPV-vaccination in Denmark, 2015. Vaccine 2019. link 44 Bonaldo G, Vaccheri A, D'Annibali O, Motola D. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. British journal of clinical pharmacology 2019. link 45 Yaju Y, Tsubaki H. Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. Japan journal of nursing science : JJNS 2019. link 46 Ran J, Yang JY, Lee JH, Kim HJ, Choi JY, Shin JY. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016. International journal of clinical pharmacy 2019. link 47 Rosenberg K, Mechcatie E. HPV Vaccination and Sexual Behaviors in Adolescents and Young Women. The American journal of nursing 2018. link 48 Oliveira CR, Rock RM, Shapiro ED, Xu X, Lundsberg L, Zhang LB et al.. Missed opportunities for HPV immunization among young adult women. American journal of obstetrics and gynecology 2018. link 49 Stanley C, Secter M, Chauvin S, Selk A. HPV vaccination in male physicians: A survey of gynecologists and otolaryngology surgeons' attitudes towards vaccination in themselves and their patients. Papillomavirus research (Amsterdam, Netherlands) 2018. link 50 Suragh TA, Lewis P, Arana J, Mba-Jonas A, Li R, Stewart B et al.. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017. British journal of clinical pharmacology 2018. link 51 Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study. Papillomavirus research (Amsterdam, Netherlands) 2018. link 52 Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine 2018. link 53 Dilley S, Scarinci I, Kimberlin D, Straughn JM. Preventing human papillomavirus-related cancers: we are all in this together. American journal of obstetrics and gynecology 2017. link 54 Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase. Drug safety 2017. link 55 Wang D, Cunningham R, Boom J, Amith M, Tao C. Towards a HPV Vaccine Knowledgebase for Patient Education Content. Studies in health technology and informatics 2016. link 56 Zhao C, Crothers BA, Ghofrani M, Li Z, Souers RJ, Hussain M et al.. Human Papillomavirus Genotyping Testing Practice in 2014: Results of a College of American Pathologists National Survey. Archives of pathology & laboratory medicine 2016. link 57 Ghofrani M, Zhao C, Davey DD, Fan F, Husain M, Laser A et al.. Update on the College of American Pathologists Experience With High-Risk Human Papillomavirus Proficiency Testing for Cytology. Archives of pathology & laboratory medicine 2016. link 58 Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Human vaccines & immunotherapeutics 2016. link 59 Yuji K, Nakada H. Compensation programs after withdrawal of the recommendation for HPV vaccine in Japan. Human vaccines & immunotherapeutics 2016. link 60 Cameron RL, Ahmed S, Pollock KG. Adverse event monitoring of the human papillomavirus vaccines in Scotland. Internal medicine journal 2016. link 61 Šubelj M, Učakar V, Kraigher A, Klavs I. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2016. link 62 Dempsey AF, Pyrzanowski J, Brewer S, Barnard J, Sevick C, O'Leary ST. Acceptability of using standing orders to deliver human papillomavirus vaccines in the outpatient obstetrician/gynecologist setting. Vaccine 2015. link 63 Zhao C, Moriarty AT, Ghofrani M, Husain M, Tambouret RH, Laucirica R et al.. Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Archives of pathology & laboratory medicine 2015. link 64 Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clinical rheumatology 2015. link 65 Lataifeh I, Obeidat N, Al-Mehaisen L, Khriesat W, Tadros R, Khader Y et al.. A survey of Jordanian obstetricians and gynecologists' knowledge and attitudes toward human papillomavirus infection and vaccination. European journal of gynaecological oncology 2014. link 66 Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiology and drug safety 2014. link 67 Harris T, Williams DM, Fediurek J, Scott T, Deeks SL. Adverse events following immunization in Ontario's female school-based HPV program. Vaccine 2014. link 68 Jain KM, Paul P, LaMontagne DS. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects. Sexual health 2013. link 69 van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 2011. link 70 Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. The International journal of risk & safety in medicine 2011. link 71 Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R et al.. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011. link 72 Grzybowski A, Jabłońska S. More on Hans Biberstein and his original ideas of vaccination against human warts and herpes infection. The American Journal of dermatopathology 2010. link 73 Leddy MA, Anderson BL, Gall S, Schulkin J. Obstetrician-gynecologists and the HPV vaccine: practice patterns, beliefs, and knowledge. Journal of pediatric and adolescent gynecology 2009. link 74 Borja-Hart NL, Benavides S, Christensen C. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System. The Annals of pharmacotherapy 2009. link 75 Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A et al.. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009. link 76 Lo B. Human papillomavirus vaccination programmes. BMJ (Clinical research ed.) 2007. link 77 Seabrook JM, Hubbard RA. Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Archives of pathology & laboratory medicine 2003. link 78 Blythe JG, Chehval MJ. Colposcopy of condylomatous men. Missouri medicine 1989. link